Royalty Pharma (RPRX) Interest Coverage Ratio (2019 - 2026)
Royalty Pharma (RPRX) reported Interest Coverage Ratio of 2.52 for Q1 2026, down 13.97% on a YoY basis from 2.93 in Q1 2025, and down 95.67% sequentially from 58.13 in Q4 2025.
Royalty Pharma (RPRX) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Royalty Pharma (RPRX) has 8 years of Interest Coverage Ratio data on file, last reported at 2.52 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio fell 13.97% year-over-year to 2.52; the trailing twelve-month figure through Mar 2026 stood at 7.1 (down 31.78% YoY), and the FY2025 full-year result was 5.07, down 11.56% from the prior year.
- Interest Coverage Ratio slipped to 2.52 in Q1 2026, from 58.13 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 449.09 in Q4 2024 to a low of 26.11 in Q4 2022.
- A 5-year average of 40.17 and a median of 1.43 in 2023 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio slumped 899.47% in 2022 and jumped 805.53% in 2023, its largest moves.
- Tracing RPRX's Interest Coverage Ratio over 5 years: stood at 26.11 in 2022, then jumped by 805.53% to 184.22 in 2023, then jumped by 143.78% to 449.09 in 2024, then plunged by 87.06% to 58.13 in 2025, then plunged by 95.67% to 2.52 in 2026.
- Business Quant data shows RPRX's Interest Coverage Ratio at 2.52 in Q1 2026, 58.13 in Q4 2025, and 5.37 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 2.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.52 |
| Dec 31, 2025 | 58.13 |
| Sep 30, 2025 | 5.37 |
| Jun 30, 2025 | 1.18 |
| Mar 31, 2025 | 2.93 |
| Dec 31, 2024 | 449.09 |
| Sep 30, 2024 | 3.82 |
| Jun 30, 2024 | 1.31 |
| Mar 31, 2024 | -0.46 |
| Dec 31, 2023 | 184.22 |
| Sep 30, 2023 | 0.90 |
| Jun 30, 2023 | 1.43 |
| Mar 31, 2023 | 2.68 |
| Dec 31, 2022 | -26.11 |
| Sep 30, 2022 | -1.02 |
| Jun 30, 2022 | -1.95 |
| Mar 31, 2022 | -1.10 |
| Dec 31, 2021 | 3.27 |
| Sep 30, 2021 | -1.45 |
| Jun 30, 2021 | -4.27 |